Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A multi-center phase 1/2 trial evaluating ibrutinib combined with MEDI4736 in relapsed or refractory lymphomas has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• MEDI4736 (Durvalumab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-06-27